CTOs on the Move

Koneksa Health

www.koneksahealth.com

 
Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Dave Hurry
Chief Data Officer Profile

Funding

Koneksa Health raised $16M on 09/28/2020

Similar Companies

TMS International

TMSi is specialized in developing of high-quality measurement systems for electrophysiological parameters such as EEG and High Density EMG. Our systems are highly versatile and have the best data quality possible.

Inclinix Inc.

Inclinix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Javan Engineering Inc

Javan Engineering Inc is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KORU Medical

The home infusion industry turns to KORU Medical Systems to help patients and medical professionals improve infusion therapy experiences and we have a passion and vision for doing just that! We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers with careful consideration to the patient experience. The company was incorporated in March 1980 and is now publicly traded on the NASDAQ Capital Market (NASDAQ: KRMD). We are located in Chester, NY (USA), just 60 miles northwest of New York City. Our primary products include the FREEDOM60® and FreedomEdge® Syringe Infusion Systems, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.